Camizestrant reduces risk of breast cancer progression by 56%
Results of a global study presented at the American Society of Clinical Oncology (ASCO) annual meeting have shown that camizestrant for advanced breast cancer can be used to treat emerging tumours.
The study was funded by AstraZeneca and co-led by researchers at The Institute of Cancer Research, London, The Royal Marsden NHS Foundation Trust and Institut Curie, Paris.
The results found that patients with advanced hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer who were given camizestrant in combination with a CDK4/6 inhibitor cut the chances of their cancer getting worse by over half (56%), allowing them to stay on first-line therapy for longer.
The SERENA-6 Phase III trial is also the first global trial to demonstrate that using circulating tumour DNA (ctDNA) blood tests to guide treatment at the right time — before clinical signs of progression appear — has a significant clinical benefit for this group of patients.
First-line therapy for HR+, HER2‑ advanced breast cancer is usually a cyclin-dependent kinase (CDK) 4 and 6 inhibitor drug plus an aromatase inhibitor (a type of hormone treatment).
Camizestrant, which was discovered and developed by AstraZeneca, is a ‘next-generation’ oral selective estrogen receptor degrader (SERD).
It works by blocking and breaking down oestrogen receptors in breast cancer cells. Camizestrant was designed to target the ESR1 mutations tested for in the ctDNA blood tests.
Camizestrant not only prevents oestrogen from attaching to cancer cells but also destroys the receptors themselves, making it harder for the cancer to resist treatment.
The SERENA-6 Phase III trial
The SERENA-6 study tested whether switching to camizestrant from an aromatase inhibitor, whilst continuing treatment with the same CDK 4/6 inhibitor to treat tumours with emerging ESR1 mutations could extend the benefit of first line treatment and delay the need for later-line therapies.
3,325 patients with HR+, HER2 negative advanced breast cancer (who had been on first-line treatment for at least six months) from 23 countries were screened for ESR1 mutations using ctDNA testing every eight to 12 weeks.
Of that number, 548 patients tested positive for ESR1 mutations during the screening period, and 315 were randomised onto the study.
Half of the patients were given camizestrant, alongside their CDK4/6 inhibitor plus a dummy pill instead of their aromatase inhibitor. Patients on the control arm continued with their aromatase inhibitor and CDK4/6 inhibitor plus a dummy pill instead of camizestrant.
The results showed that the camizestrant combination reduced the risk of breast cancer progression or death by 56% based on the reported hazard ratio of 0.44.
The median progression free survival time for patients taking the camizestrant combination was 16 months, compared with 9.2 months for patients on the control arm.
The results also showed that the therapy regime reduced the risk of a deterioration in patients’ general health and quality of life by 47% (based on the reported hazard ratio of 0.53), compared with the control group, demonstrating the benefit of patients remaining on first-line therapy.
Co-principal investigator Professor Nick Turner, Professor of Molecular Oncology at The Institute of Cancer Research, London, and Director of Clinical Research and Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust, said: “This is a pivotal moment in breast cancer care. These results demonstrate that using liquid biopsy blood tests to spot emerging resistance in tumours, before they start to grow and make the patient unwell, can guide early intervention with camizestrant to delay disease progression in patients with ESR1 mutations.
“This proactive approach not only extends the benefit of first line therapy but also redefines how we think about drug resistance in this type of breast cancer. This is a potential new treatment strategy in oncology to treat developing resistance before it causes disease progression.”
Diana Spencer, Senior Digital Content Editor, DDW
